ADC slides on latest Zynlonta update
Deteriorating efficacy and a treatment-related death with Zynlonta plus Columvi spook investors.
AACR 2025 preview – new preclincal approaches abound
Novel targets including Ly6E and LRRC15 feature alongside more popular mechanisms.
Amgen packs up in Claudin6
Meanwhile, Torl BioTherapeutics appears to be catching up with BioNTech.
